Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients

Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients

Objectives: This pilot retrospective study examined the role of continuous low-dose maintenance immunomodulatory treatment (IMT) as an adjunct to rituximab (RTX) rescue therapy in severe pemphigus vulgaris (PV) and pemphigus foliaceus (PF) after a complete response (CR) to RTX was achieved. Material...

Full description

Bibliographic Details
Main Authors: Jordan M. Keeley, Stephanie L. Bevans, Tarannum Jaleel, Naveed Sami
Format: Article
Language:English
Published: Taylor & Francis Group 2019-05-01
Series:Journal of Dermatological Treatment
Subjects:
immunomodulatory therapy
pemphigus foliaceus
pemphigus vulgaris
rituximab
Online Access:http://dx.doi.org/10.1080/09546634.2018.1510173

Internet

http://dx.doi.org/10.1080/09546634.2018.1510173

Similar Items